A Systemic, Heterogeneous Disease
Recognizing Sjögren's Disease as Serious and Systemic: Q&A With Dr Ghaith Noaiseh
Shed light on the significant patient burden of Sjögren’s disease, focusing on underrecognized systemic manifestations, multiorgan involvement, and potential complications, with Medical Expert Dr Ghaith Noaiseh.
Expert Exchange on Sjögren’s Disease: An Autoimmune Disease That Can Be Serious and Progressive
Sjögren’s disease is more than dryness, often featuring sicca symptoms. Join Teja Kapoor, MD, Adam Doré, DO, and Erin Siceloff, PA, as they explore the systemic and heterogeneous nature of this serious disease.
Expert Exchange on Sjögren’s Disease: Uncovering Systemic Disease Burden Through ESSDAI Domains
Discover how ESSDAI-based questions help reveal systemic involvement in Sjögren’s disease. Teja Kapoor, MD, and Adam Doré, DO, highlight key domains, including glandular, articular, cutaneous, and lymphadenopathy.
Beyond Dryness: The Hidden Impact of Systemic Manifestations in Sjögren's Disease
Delve into the heterogeneous nature of SjD with insights from Dr Eric Anderson. This resource examines the symptom burden, multisystem organ involvement, and long-term health impacts of this systemic autoimmune disease that can be serious and progressive.
B-Cell–Driven Disease
Expert Exchange on Sjögren’s Disease: A B-Cell-Driven Disease With Inadequate Treatment Options
Teja Kapoor, MD, and Adam Doré, DO, explore the underlying pathogenesis of Sjögren’s disease, including the critical role of B cells, and discuss unmet treatment needs.
Sjögren’s Disease Pathophysiology: B Cells, BAFF, and More With Alfred Kim, MD, PhD
Alfred Kim, MD, PhD, explores the B-cell–driven mechanisms underlying Sjögren’s disease and how B-cell hyperactivity and elevated BAFF levels are thought to contribute to its pathogenesis.
The Critical Role of B Cells and BAFF in Sjögren’s Disease Pathogenesis
Discover the B-cell–driven nature of Sjögren’s disease and the impact of B-cell hyperactivity and elevated BAFF levels on disease pathogenesis, with insights from Dr Alfred Kim.
Your sicca plus Patients
Recognizing Disease Activity Matters: A Closer Look Into Your Patients Who Are "Sicca Plus" With Tara Rizvi, MD
Tara Rizvi, MD, introduces “Sicca Plus,” a practical framework to help rheumatologists identify patients with Sjögren’s disease who may be eligible for biologic therapy, and reviews ESSDAI-based questions that can help uncover systemic manifestations.
Expert Exchange on Sjögren’s Disease: Identifying Your Patients Who Are "Sicca Plus" May Help Enable Timely, Targeted Intervention With Biologic Therapy
Learn how the "sicca plus" framework can help identify patients with Sjögren's disease who may be eligible for biologic therapy. Teja Kapoor, MD, Adam Doré, DO, and Erin Siceloff, PA, illustrate its uses through patient cases.
Understanding "Sicca Plus" — A Framework to Identify Patients With Sjögren’s Disease Who May Be Eligible for Biologic Therapy
Explore the “Sicca plus” framework, which builds on the ESSDAI and current guidelines to assess systemic involvement and guide biologic treatment decisions in Sjögren’s disease, featuring insights from Dr Jaishree Manohar.